Article
Cover
RJPS Journal Cover Page

RJPS Vol No: 14 Issue No: 3 eISSN: pISSN:2249-2208

Article Submission Guidelines

Dear Authors,
We invite you to watch this comprehensive video guide on the process of submitting your article online. This video will provide you with step-by-step instructions to ensure a smooth and successful submission.
Thank you for your attention and cooperation.

Short Communication
Vasanth PM*,1, Venkatesh Goli2, Paul Richard3, V Sarath4, DS Charan5, Deepak K6,

1Vasanth PM, Faculty, Department of Pharmaceutical Analysis, SVU College of Pharmaceutical Sciences, SV University, Tirupati, India.

2Department of Pharmaceutics, SVU College of Pharmaceutical Sciences, SV University, Tirupati-517502, AP, India

3Department of Pharmaceutical Analysis, Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore.

4SVU College of Pharmaceutical Sciences, SV University, Tirupati-517502, AP, India.

5Seven Hills College of Pharmacy, Tirupati, AP, India.

6Ranchi College of Pharmacy, Ranchi, Jharkhand, India.

*Corresponding Author:

Vasanth PM, Faculty, Department of Pharmaceutical Analysis, SVU College of Pharmaceutical Sciences, SV University, Tirupati, India., Email: vasanthpharma@gmail.com
Received Date: 2023-01-01,
Accepted Date: 2023-01-01,
Published Date: 2023-03-31
Year: 2023, Volume: 13, Issue: 1, Page no. 33-38, DOI: 10.26463/rjps.13_1_7
Views: 818, Downloads: 25
Licensing Information:
CC BY NC 4.0 ICON
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0.
Abstract

Background: Nimesulide is a non-steroidal anti-inflammatory selective inhibitor of the enzyme cyclooxygenase with analgesic and antipyretic properties. It is approved to treat acute pain, symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years age.

Objective: This article describes the recent research on the bioequivalence of six brands of Nimesulide tablets. Due to the large variety of Nimesulide tablet brands accessible in the Indian market, medical practitioners face a tough challenge of selecting the best brand or using alternative treatments. The study presented assessed all six tablet brands in accordance with Indian Pharmacopoeia (IP) guidelines, and the appropriate methods were provided for choosing the best options.

Methodology: All six tablet brands were evaluated utilizing in vitro tests using various evaluation techniques. Six different brands of tablets were used in the in vitro dissolving experiment and all of the tablets cleared the standards for general quality evaluation tests such as hardness, friability, disintegration time, and dissolve time. All of the tested brands met the requirements for the disintegration time. With the exception of brand names Nimek and Bigesic, every brand released more than 45% of the Nimesulide after 30 min. Auronim, Novogesic, Zega, and Nise have a very sluggish rate of dissolution, which indicates that their bioavailability is most likely to be low. The variations in the reported dissolving profiles could be due to differences between the manufacturers in terms of formulation ingredients, the physical form of medicine used in the tablet and the manufacturing method.

Results: The result emphasizes the importance of continuous monitoring of new Nimesulide brands introduced to the drug market to ensure bioequivalence and compliance with pharmacopoeia standards.

Conclusion: The results conclude that with the exception of Nimek and Biogesic, all of the Nimesulide tablet brands investigated appear to have a high dissolution rate, with extremely good bioavailability releasing >45 percent Nimesulide within 30 minutes and thus satisfied the Indian Pharmacopoeia criterion for uncoated tablet dissolution. Auronim, Zega, Nise and Novogesic are interchangeable and bioequivalent.

<p><strong>Background:</strong> Nimesulide is a non-steroidal anti-inflammatory selective inhibitor of the enzyme cyclooxygenase with analgesic and antipyretic properties. It is approved to treat acute pain, symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years age.</p> <p><strong>Objective:</strong> This article describes the recent research on the bioequivalence of six brands of Nimesulide tablets. Due to the large variety of Nimesulide tablet brands accessible in the Indian market, medical practitioners face a tough challenge of selecting the best brand or using alternative treatments. The study presented assessed all six tablet brands in accordance with Indian Pharmacopoeia (IP) guidelines, and the appropriate methods were provided for choosing the best options.</p> <p><strong>Methodology:</strong> All six tablet brands were evaluated utilizing <em>in vitro</em> tests using various evaluation techniques. Six different brands of tablets were used in the<em> in vitro</em> dissolving experiment and all of the tablets cleared the standards for general quality evaluation tests such as hardness, friability, disintegration time, and dissolve time. All of the tested brands met the requirements for the disintegration time. With the exception of brand names Nimek and Bigesic, every brand released more than 45% of the Nimesulide after 30 min. Auronim, Novogesic, Zega, and Nise have a very sluggish rate of dissolution, which indicates that their bioavailability is most likely to be low. The variations in the reported dissolving profiles could be due to differences between the manufacturers in terms of formulation ingredients, the physical form of medicine used in the tablet and the manufacturing method.</p> <p><strong>Results:</strong> The result emphasizes the importance of continuous monitoring of new Nimesulide brands introduced to the drug market to ensure bioequivalence and compliance with pharmacopoeia standards.</p> <p><strong>Conclusion: </strong>The results conclude that with the exception of Nimek and Biogesic, all of the Nimesulide tablet brands investigated appear to have a high dissolution rate, with extremely good bioavailability releasing &gt;45 percent Nimesulide within 30 minutes and thus satisfied the Indian Pharmacopoeia criterion for uncoated tablet dissolution. Auronim, Zega, Nise and Novogesic are interchangeable and bioequivalent.</p>
Keywords
Nimesulide, Dissolution, Bioequivalence, Bioavailability, Pharmacopoeia
Downloads
  • 1
    FullTextPDF
Article
Introduction

Owing to its anti-inflammatory effectiveness and therapeutic safety profile, Nimesulide (N- (4-Nitro-2- phenoxyphenyl) methane sulphonamide is categorised as an alkyl sulphonamide and is a non-steroidal anti-inflammatory selective inhibitor of the enzyme cyclooxygenase (COX) type 2. It is a weak acid that is almost insoluble in water and appears as a pale-yellow powder, crystalline, somewhat unctuous to the touch, odourless, and non-hygroscopic. Oral Solid Dosage Forms (OSDF) are most commonly utilised by the population and most commonly prescribed by health experts, and they have various advantages over other pharmaceutical forms, including low production costs and good stability. When compared to liquid forms, certain active principles have better physicochemical and microbiological qualities, as well as a lesser sense of disagreeable taste and odour.1-2

OSDFs present as a unit dosage form with greater dose precision and less variability in content. They are also lighter and more compact than other oral dosage forms making them easier to carry. They can be manufactured on a larger scale, are easy to administer eliminating the need for specialised technical people.3

Oral tablets are used to deliver a specific and specified dose of medicine to the human body via the gastrointestinal tract. Studies on medication bioavailability from various dosage forms indicated that, in many cases, tablets containing the same drug and drug content did not have the same therapeutic benefit. The tablet formulation ingredients, physical form of the drug employed in the tablet, and tablet manufacturing method vary from manufacturer to manufacturer, and can be responsible for variations in observed dissolution profiles and therapeutic effects.4

Pharmaceutical availability, often known as in vitro availability, is one component of medication bioavailability. The dissolve test is done on tablets and is thought to be sensitive, reliable, and reasonable for predicting in vivo drug availability behaviour.5

In the Indian market, a wide range of Nimesulide formulations are available. Because there are several brands of Nimesulide available in our medication market today, doctors and pharmacists encounter a tough challenge of selecting an appropriate brand or considering alternate uses. Furthermore, there are emerging worries that different Nimesulide formulations may have varying bioavailability and that resistance development would be accelerated if suboptimal doses are utilised. Despite the fact that Nimesulide tablets are used in a variety of ways in India, there no studies reported on their bioavailability and bioequivalence.6-10

As a result, the current study was designed to evaluate various in vitro quality control characteristics of six commercially available Nimesulide tablets, with a focus on dissolution rate investigations.

Methods and Materials

Six different brands of Nimesulide pills of 100 mg potency were acquired from a local market in Tirupati, Andhra Pradesh, India. The products were labelled with the letters A, B, C, D, E and F. At the time of the study, all the selected products were manufactured within the previous six months. All brands of tablets had a shelf life of 36 months from the date of manufacture. According to Indian Pharmacopoeia (IP) procedures, all brands of tablets were examined for weight uniformity, hardness, friability, content, disintegration time, and dissolving profile. Vernier calipers were used to determine the size and shape of the tablets. The tablet hardness was determined using a Monsanto tablet hardness tester. Tablet friability was determined using a Roche friability tester. All trials were repeated three times, and the averages were given on the table.11-14

Size and shape

The diameter and thickness of the Nimesulide tablet were measured with a Vernier caliper. The determinations were made in triplicates, and the averages were reported.

Hardness test

Monsanto hardness tester was used to measure the hardness of Nimesulide tablets. This tester works on the same premise as a pair of pliers. The power required to break the tablet is measured in kilograms, and most oral pills have a hardness of 4 to 10 kg/cm2 . The average tablet hardness was computed and reported.

Friability test

The Roche Friability testing was used to determine the friability of Nimesulide tablets. The tablets were subjected to the combined effects of abrasions and stress using a plastic chamber that revolves at 25 rpm for 100 revolutions. In addition, the percent friability

Weight variation

By individually weighing 20 pieces at random on an electronic balance, the average weight and maximum % variance was calculated.15-18

Drug content

The drug content was determined using the procedure given in I.P. The solution was passed through a 0.45 nylon disc filter and tested for drug content using a UVvisible spectrophotometer at 397 nm.

Disintegration test

The average disintegration time was calculated after performing the I.P method on six tablets using the Disintegration test apparatus with disc in distilled water medium at 37oC.

Dissolution test

In vitro dissolution experiments of tablet formulations were carried out in 900 mL of dissolving medium, pH 7.4 phosphate buffer IP using a USP XXI type 2 dissolution rate test instrument at a speed of 50 rpm and a temperature of 37 ± 1°C. At different time intervals, a 5 mL aliquot was removed and filtered through a 0.45 m nylon disc filter, each sample was replaced with 5 mL of fresh dissolving medium. The filtered samples were diluted as needed and Nimesulide absorbance was measured at 397 nm.19-25

Results

According to Indian Pharmacopoeia (IP) rules, the in vitro dissolving investigation was performed on six brands of Nimesulide tablets using the paddle method. Other quality control tests like hardness and disintegration time were also performed and all of these different brands of Nimesulide pills met compendial standards. All of the brands tested met the disintegration time criteria.

Discussion

The general appearance of tablets of all brands was as follows: colour-sunset yellow for brands B, C and F, and quinoline yellow for brands A, D, and E. All brands had a round, slightly curved, biconvex form. All of the brands had high hardness strength, which is necessary for safe handling and shipping. The hardness was determined to be between 3.8 and 4.4 kg. All brands had less than 1% friability, with brand E having the lowest friability of 0.31% and brand A having the highest friability of 0.68%. All brands had acceptable friability and hardness limitations, demonstrating adequate mechanical strengths. Nimesulide content in each tablet brand was consistent with I.P.

The weight variation test, as required by I.P., was cleared by all tablet brands. All pill brands passed the I.P disintegration time, indicating that they will breakdown fast in gastrointestinal tract fluid after oral administration. However, the disintegration time varied greatly between brands. Formulation F had a disintegration time of only 1 minutes and 29 seconds, but formulation E had a disintegration time of 5 minutes and 52 seconds. Except for brand C and E, brands A, B, D, and F passed the I.P dissolving test.

Conclusion

Our in vitro dissolution results revealed that the bioavailability of Nimesulide varied significantly between the several brands of Nimesulide tablets. Almost all of the brands cleared all of the official I.P. testing. The formulation ingredients in the tablet, the physical shape of the medicine in the tablet form, and the manufacturing process differed from manufacturer to manufacturer, accounting for the diversity in reported dissolving profiles. In conclusion, our findings demonstrate that, with the exception of C and E, all the Nimesulide tablet brands studied appeared to have a high dissolution rate and thus have extremely good bioavailability. >45 percent of Nimesulide was released within 30 minutes thus clearing the Indian Pharmacopoeia criterion for uncoated tablet dissolution. Samples A, B, D and F were bioequivalent and interchangeable. However, in vivo research is required to further validate the in vitro predictions. This study emphasises the importance of continuous monitoring of new products launched into our medicine market in order to ensure bioequivalence and compliance with pharmacopoeia requirements.

Conflict of interest

None

Supporting File
References
  1. Rodrigues MB, Barreto ACH, Neto EMR, de Araujo TG. Comparative study among drying techniques in the development of nimesulide tablet. J Young Pharm 2020;12(1):42-47.
  2. Dellis D, Giaginis C, Tsantili-Kakoulidou A. Physicochemical profile of nimesulide. Exploring the interplay of lipophilicity, solubility and ionization. J Pharm Biomed Anal 2007;44(1):57- 62.
  3. Brazil. Agência Nacional de Vigilância Sanitária (ANVISA); Farmacopéia Brasileira, 5th Ed. Brasilia, Brasil. 2010;1.
  4. Ozkan Y, Ozalp Y, Savaşer A, Ozkan SA. Comparative dissolution testing of paracetamol commercial tablet dosage forms. Acta Pol. Pharm 2000;57(1):33-41. 
  5. Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P. Cyclo-oxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-82.
  6. Jain K et al. Controversial drug may get government consent. Times of India (Mumbai) 2002 Dec. 17; 7.
  7. Rajwadkar K et al. Pediatric nimesulide withdrawn from market. Nagpur: The Indian Express 2003 Jan. 2; 13.
  8. Chow CS, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker; 1992. p. 1–2.
  9. Allen LV, Ansel HC. Ansel’s pharmaceutical dosage forms and drug delivery systems: Tenth edition. Baltimore: Wolters Kluwer Health; 2014.
  10. Parikh DM. Handbook of pharmaceutical granulation technology. Second Edition. CRC Press; 2005.
  11. Michael E, Aulton PY. Design of dosage forms. In: Aulton’s Pharmaceutics the Design and Manufacture of Medicines. United Kingdom: Elsevier Health Sciences; 2013.
  12. Tardos GI, Khan MI, Mort PR. Critical parameters and limiting conditions in binder granulation of fine powders. Powder Technol 1997;94(3):245-58.
  13. Fernandes TRP. Pharmacotechnical development and validation of analytical methodology for coated tablets based on potassium diclofenate. Master dissertation, Postgraduate Program in Pharmaceutical Sciences, Federal University of Pernambuco, Brazil. 2003.
  14. Master dissertation, Postgraduate Program in Pharmaceutical Sciences, Federal University of Pernambuco. Recife. 2000.
  15. In vitro dissolution. In: The US Pharmacopoeia Asian ed. Rockwell MD: US Pharmaceutical Convention, Inc; 2000. p. 1941-43.
  16. British Pharmacopoeia. London: The Stationery Office; 2001. p. 1183
  17. Lachman L, Liberman HA, Kanig JL. The theory and practice of industrial pharmacy. Third edition. Varghese Publishing House; 2009. p. 328
  18. Troy DB. Remington: The science and practice of pharmacy. 21st edition. Lippincott Williams and Wilkins; 2005.
  19. Aulton ME. Aulton’s Pharmaceutics- the design and manufacture of medicine. 3rd edition. Edinburgh: Churchill Livingstone; 2007. p. 404-414.
  20. Ansel HC, Popovich NG, Allen LV. Pharmaceutical dosage forms and drug delivery systems. 9th edition. Baltimore: Wolters Kluwer/Lippincott Williams and Wilkins; 2009. p. 227-257.
  21. British Pharmacopoeia, licensing division HMSO, London stationary office, 6th edition volume-II, 2010, 1512
  22. United States Pharmacopeia, United States Pharmacopeia / National Formulary (USP25/NF20). 2002, Rockville, MD: United States Pharmacopeia Convention Inc.
  23. The Indian Pharmacopoeia, Government of India, Ministry of health and family welfare, Controller of publication, New Delhi, Volume -1,2007, 185-189.
  24. The Merck Index an Encyclopedia of chemicals, drugs and biological, Merck and co. Inc., White house station, New Jersey, thirteenth edition, 2000; 1177.
  25. Prakash KP, Narayana R, Shantakumari K, Laxmi N. Spectrophotometric estimation of nimesulide trihydrate in bulk and pharmaceutical dosage form. E-Journal of Chemistry, 694.
HealthMinds Logo
RGUHS Logo

© 2024 HealthMinds Consulting Pvt. Ltd. This copyright specifically applies to the website design, unless otherwise stated.

We use and utilize cookies and other similar technologies necessary to understand, optimize, and improve visitor's experience in our site. By continuing to use our site you agree to our Cookies, Privacy and Terms of Use Policies.